We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Testing for Specific Genetic Biomarkers Could Diagnose SARS-CoV-2 Infection and Predict COVID-19 Severity

By LabMedica International staff writers
Posted on 27 Oct 2021
Print article

Scientists have discovered specific genetic biomarkers that not only show who is infected with COVID-19, but also offer insights into how severe the disease might be, thus filling a major diagnostic gap.

The new study by scientists at the University of Colorado School of Medicine (Aurora, CO, USA) suggests that specific signals from a process called DNA methylation varies between those infected and those not infected with SARS-CoV-2. And they can indicate the severity of the disease even in the early stages. DNA methylation, critical in how cells function, is an epigenetic signaling tool that cells use to turn genes off. Any mistakes in the process can trigger a variety of disease. The researchers believe that paying attention to these signals could help fill a needed gap in the current world of COVID testing.

Most COVID-19 antigen or rapid tests are dependent on viral strains and can carry high false negative rates. They do not predict if the virus is viable and replicating, nor do they predict clinical outcomes. A pre-symptomatic patient may test negative for the SARS-CoV-2 virus while patients who have recovered may still test positive despite no longer being infectious. The researchers did not know of any test that can predict the clinical course of COVID-19.

With that in mind, they analyzed the epigenome in blood samples from people with and without COVID-19. They did this by customizing a tool from Illumina called the Infinium Methylation EPIC array to enhance immune response detection. Researchers then profiled peripheral blood samples from 164 COVID-19 patients and 296 control patients. The peripheral blood DNA samples were collected from patients seen at UC Health and tested for SARS-CoV-2 epigenetic signatures starting March 1, 2020. The researchers discovered specific genetic markers of SARS-CoV-2 infection along with indications of how severe the disease might be. According to the researchers, the findings could ultimately lead to a new and more accurate way to test for COVID-19.

“I think this study is a tremendous proof-of-concept in the realm of COVID-19 testing, one that can be applied to other diseases,” said the study’s lead author, Kathleen Barnes, PhD, professor at the CU School of Medicine. “It’s a major move forward in the world of precision medicine.”

“We are exploring how this platform could add value to the COVID diagnostic world,” she said. “We think it adds value to knowing what patients develop more serious disease. This could tell you if you could ride out the infection or if it is likely to get worse.”

Related Links:
University of Colorado School of Medicine 

Gold Supplier
SARS-CoV-2 Multiplex Real-Time RT-PCR Assay
GSD NovaPrime Plus SARS-CoV-2
Pancreatic Elastase ELISA Kit
Pancreatic Elastase ELISA
Silver Supplier
Bacteriuria Test Strips
MAST Bacteruritest Strips
Vented Safety Enclosures
VSE Balance Enclosures

Print article



view channel
Image: Atellica Solution (Photo courtesy of Siemens Healthineers)

Siemens Introduces New Intelligent, Integrated IVD Solutions Virtually at EUROMEDLAB 2021

Siemens Healthineers (Erlangen, Germany) introduced new intelligent, integrated IVD solutions virtually at the XXIV IFCCEFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab... Read more


view channel
Image: The Luminex 200 Instrument System sets the standard for multiplexing, providing the ability to perform up to 100 different tests in a single reaction volume on a flow cytometry-based platform (Photo courtesy of Luminex Corp)

Inflammatory Cytokines Measured in Infants Born to Preterm Preeclamptic Mothers

Preeclampsia is both a vascular and inflammatory disorder. The pathophysiology of preeclampsia is complex and rooted in the interplay between maternal and placental factors with the key characteristics... Read more


view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more


view channel
Image: The Ventana BenchMark Ultra autostainer is for cancer diagnostics with automation and the test menu include IHC, ISH, and FITC tests (Photo courtesy of Ventana Medical System)

Specific Biomarker Investigated for Triple-Negative Breast Cancer Diagnosis

Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and comprises a heterogeneous... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global Lateral Flow Assay Market to Reach Nearly USD 6.5 Billion by 2031 Due to Surge in Demand for Rapid POC Testing

The global lateral flow assay market is projected to grow at a CAGR of around 5% from USD 3.7 billion in 2020 to over USD 6.4 billion by 2031, driven by the growing adoption of home-based lateral flow... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.